NASDAQ NMS - GLOBAL MARKET · CRSP
+0.29% · +$0.1465 · Vol 1.2M
CRISPR Therapeutics AG

CRISPR Therapeutics AG

Biotechnology
$50.38

Veridion Score

Loading
Score loading…
Veridion Score History · 90D

Composite trend over time

LOADING HISTORY…
REFRESHES DAILY
AI Analysis
Sovereign

Why is CRSP moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About CRISPR Therapeutics AG
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Founded
Listed
2016
Employees
393
HQ
CH

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Key statistics

Real vendor fields plus Veridion-computed history. Missing fields stay blank.

Open
$49.79
Day high
$51.24
Day low
$49.71
Previous close
$50.23
52W high
$50.38
-0.01% from high
52W low
$49.44
100% of range
Market cap
$4.9B
P/E
EPS
Dividend yield
Beta
Shares out
98.5M
Float
Volume
1.2M
Avg volume
VWAP
$50.27
Next earnings
Price history computed in-house
1W
+1.89%
1M
+1.89%
3M
+1.89%
1Y
+1.89%
YTD
+1.89%
SMA 50 $50.07 · above
SMA 200 $50.07 · above
52W position 100%
Veridion warehouse edge

Warehouse intelligence for CRSP.

Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Loading quarterly statements…
SEC Form 4 ledger

CRSP insider activity

CRISPR Therapeutics AG

Score
Coverage building
Pressure
Net buying
Filings
34
Buys / sells
7 / 27
Net value
$37.9M
Insiders
6
Named filers
PN
Patel Naimish
Insider
Leadership
KR
KASINGER JAMES R.
Insider
Leadership
KS
Kulkarni Samarth
Insider
Leadership
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Net buying: $37.9M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing dateTrade dateInsiderTitleTypePriceQtyOwnedValueReceipt
2026-06-012026-05-29Patel NaimishInsidersell$55.623,78619,357$211KSEC Form 4
2026-03-242026-03-23KASINGER JAMES R.Insidersell$46.783,18294,308$149KSEC Form 4
2026-03-242026-03-23Kulkarni SamarthInsidersell$46.7810,020255,501$469KSEC Form 4
2026-03-242026-03-23Prasad RajuInsidersell$46.783,70815,565$173KSEC Form 4
2026-03-172026-03-16Patel NaimishInsidersell$48.263,15013,143$152KSEC Form 4
Full Form 4 history requires Sovereign

Showing 5 recent rows. Sovereign unlocks 29 additional rows, full sorting, and the named-filer history.

Upgrade to Sovereign · $25/mo
Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Loading PTR filings…
Federal contracts

CRSP contract awards, year to date.

Public federal awards linked to this ticker.

Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CRSP in this window.
Lobbying spend

CRSP lobbying filings, year to date.

Registered lobbying filings matched to CRISPR Therapeutics AG.

Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CRSP in this window.
Latest news · CRSP
Refresh interval: 5 minutes · Source: Market news insights
Loading articles…
Analyst ratings
Sovereign unlock shows live analyst consensus for CRSP.
Options
Sovereign unlock shows live options positioning for CRSP.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.